The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy | HIV | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
Palella  FJDelaney  KMMoorman  AC  et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.  N Engl J Med 1998;338853- 860PubMedGoogle ScholarCrossref
2.
Mocroft  ALedergerber  BKatlama  C  et al.  Decline in the AIDS and death rates in the EuroSIDA study: an observational study.  Lancet 2003;36222- 29PubMedGoogle ScholarCrossref
3.
Hammer  SMKathleen  ESHughes  MD  et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less.  N Engl J Med 1997;337725- 733PubMedGoogle ScholarCrossref
4.
Cameron  DWHearth-Chiozzi  MDanner  S  et al.  Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease.  Lancet 1998;351543- 549PubMedGoogle ScholarCrossref
5.
Ledergerber  BEgger  MOpravil  M  et al.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study: Swiss HIV Cohort Study.  Lancet 1999;353863- 868PubMedGoogle ScholarCrossref
6.
Detels  RTarwater  PPhair  JPMargolick  JRiddler  SAMunoz  AMulticenter AIDS Cohort Study, Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis.  AIDS 2001;15347- 355PubMedGoogle ScholarCrossref
7.
Paredes  RMocroft  AKirk  O  et al.  Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.  Arch Intern Med 2000;1601123- 1132PubMedGoogle ScholarCrossref
8.
Mellors  JWMunoz  AGiorgi  JV  et al.  Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.  Ann Intern Med 1997;126946- 954PubMedGoogle ScholarCrossref
9.
Egger  MMay  MChêne  G  et al.  Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: collaborative analysis of prospective studies.  Lancet 2002;360119- 129PubMedGoogle ScholarCrossref
10.
Antiretroviral Therapy (ART) Cohort Collaboration, Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.  Lancet 2003;362679- 686PubMedGoogle ScholarCrossref
11.
Michelet  CArvieux  CFrancois  C  et al.  Opportunistic infections occurring during highly active antiretroviral treatment.  AIDS 1998;121815- 1822PubMedGoogle ScholarCrossref
12.
Ledergerber  BEgger  MErard  V  et al.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy.  JAMA 1999;2822220- 2226PubMedGoogle ScholarCrossref
13.
Li  TSTubiana  RKatlama  CCalvez  VMohand  HAAutran  B Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease.  Lancet 1998;3511682- 1686PubMedGoogle ScholarCrossref
14.
Race  EMAdelson-Mitty  JKriegel  GR  et al.  Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.  Lancet 1998;351252- 255PubMedGoogle ScholarCrossref
15.
Karavellas  MPPlummer  DJMacdonald  JC  et al.  Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy.  J Infect Dis 1999;179697- 700PubMedGoogle ScholarCrossref
16.
DeSimone  JAPomerantz  RJBabinchak  TJ Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy.  Ann Intern Med 2000;133447- 454PubMedGoogle ScholarCrossref
17.
Ives  NJGazzard  BGEasterbrook  PJ The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic.  J Infect 2001;42134- 139PubMedGoogle ScholarCrossref
18.
Ledergerber  BTelenti  AEgger  MSwiss HIV Cohort Study, Risk of HIV related Kaposi’s sarcoma and non-Hodgkin’s lymphoma with potent antiretroviral therapy: prospective cohort study.  BMJ 1999;31923- 24PubMedGoogle ScholarCrossref
19.
Centers for Disease Control, 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.  MMWR Recomm Rep 1992;41 ((RR-17)) 1- 19PubMedGoogle Scholar
20.
SAS Institute Inc, SAS/STAT Software: Changes and Enhancements Through Release 6.12.  Cary, NC SAS Institute Inc1997;
21.
d’Arminio Monforte  ACozzi-Lepri  ARezza  G  et al. ICONA Study Group, Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients.  AIDS 2000;14499- 507PubMedGoogle ScholarCrossref
22.
van Roon  ENVerzijl  JMJuttmann  JRLenderink  AWBlans  MJEgberts  ACG Incidence of discontinuation of highly active antiretroviral therapy (HAART) and its determinants.  J Acquir Immune Defic Syndr Hum Retrovirol 1999;20290- 294PubMedGoogle ScholarCrossref
23.
Pakker  NGNotermans  DWDe Boer  RJ  et al.  Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.  Nat Med 1998;4208- 214PubMedGoogle ScholarCrossref
24.
Autran  BCarcelain  GLi  TS  et al.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.  Science 1997;277112- 116PubMedGoogle ScholarCrossref
25.
Jones  JLHanson  DLDworkin  MSKaplan  JEWard  JW Trends in AIDS-related opportunistic infections among men who have sex with men and among injecting drug users, 1991-1996.  J Infect Dis 1998;178114- 120PubMedGoogle ScholarCrossref
26.
Nightingale  SDCameron  DWGordin  FM Two controlled trials of rifabutin prophylaxis against MAC infection in AIDS.  N Engl J Med 1993;329828- 833PubMedGoogle ScholarCrossref
27.
Masur  HKaplan  JEHolmes  KKUS Public Health Service; Infectious Diseases Society of America, Guidelines for preventing opportunistic infections among HIV-infected persons—2002: recommendations of the US Public Health Service and the Infectious Disease Society of America.  Ann Intern Med 2002;137435- 478PubMedGoogle ScholarCrossref
28.
Phillips  ANLazzarin  AGonzales-Lahoz  J  et al.  Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome.  J Clin Epidemiol 1996;491253- 1258PubMedGoogle ScholarCrossref
29.
Miller  VSabin  CPhillips  AN  et al.  The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.  AIDS 2000;142129- 2136PubMedGoogle ScholarCrossref
30.
Andrè  PGroettrup  MKleinerman  P  et al.  An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.  Proc Natl Acad Sci U S A 1998;9513120- 13124PubMedGoogle ScholarCrossref
31.
Cassone  ADe Bernardis  FTorosantucci  ATaconelli  ETamburello  MCauda  R In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors.  J Infect Dis 1999;180448- 453PubMedGoogle ScholarCrossref
Original Investigation
February 28, 2005

The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy

The Antiretroviral Therapy Cohort Collaboration*
Author Affiliations

*Authors: The Writing Committee members for the Antiretroviral Therapy Cohort Collaboration are Antonella d’Arminio Monforte, MD, Caroline A. Sabin, PhD, Andrew Phillips, PhD, Jonathan Sterne, PhD, Margaret May, PhD, Amy Justice, PhD, Francois Dabis, PhD, Sophie Grabar, PhD, Bruno Ledergerber, PhD, John Gill, MBChB, Peter Reiss, PhD, and Matthias Egger, MD, MSc.

Arch Intern Med. 2005;165(4):416-423. doi:10.1001/archinte.165.4.416
Abstract

Background  Although the incidence of most AIDS events declines after initiation of highly active antiretroviral therapy (HAART), this decline is more rapid for some conditions than others. We herein describe the decline in incidence of AIDS-defining events among 12 574 antiretroviral-naive individuals who started HAART in the Antiretorviral Therapy Cohort Collaboration and determined whether the rate of decline is similar for events with different etiologies.

Methods  Rates of AIDS were calculated for the periods 0 to 3, 4 to 6, 7 to 12, 13 to 24, and 25 to 36 months after starting HAART. Changes in incidence over time were investigated using Poisson regression.

Results  During 22 958 person-years of follow-up, 928 AIDS events developed (25.3% viral, 24.6% bacterial, 20.7% fungal, 8.1% protozoal, and 21.2% other). The incidence of any AIDS event declined from 129.3 (95% confidence interval [CI], 116.7-141.8) per 1000 person-years in the first 3 months to 13.2 (95% CI, 9.4-17.0) in the third year after starting HAART (P<.001). The rate of decline in incidence was greatest for events with a viral etiology (87.0% per year) and lowest for those with a fungal etiology (54.0% per year). In the third year, fungal events represented 37.0% of AIDS events that occurred. After adjustment for the CD4 count and human immunodeficiency virus 1 RNA level, changes in the incidence of bacterial and viral events from months 0 to 6 and 7 to 12 remained significant, suggesting that changes in these markers did not fully explain the changes in incidence seen.

Conclusion  Although the incidence of all AIDS-defining events decreased substantially after starting HAART, the pattern of decline was most pronounced for events with a viral etiology.

×